Welcome to the November edition of our newsletter!
For 40 years, we’ve helped scientists harness the full potential of biology with next-generation technology. Here we share the latest in automated, end-to-end solutions that span research disciplines to advance scientific discovery and improve the quality of human life worldwide.
UPGRADE BEFORE THE NEW YEAR
Secure Your New Automation System by Year-End and Save!
As the holiday season approaches, we’re here to bring some cheer to your lab—kick off 2025 with a brand-new automation system, delivered by December 31! With this exclusive holiday offer, you’ll also receive two days of FREE hands-on training in Q1 2025 to ensure you’re ready to hit the ground running.
Why Act Now?
By securing your system and training now, you’ll:
Maximize Your Budget: Invest in essential equipment before year-end, optimizing this year’s budget.
Minimize Downtime: Get up and running quickly with trained staff, reducing the time and resources often lost during onboarding.
Accelerate Your Research Goals:Begin 2025 fully prepared, advancing projects faster and more efficiently.
Gain a Competitive Edge: Start the year prepared while others might still be waiting for equipment or support.
How to Unwrap This Offer:
By securing your system and training now, you’ll:
Review your budget and identify workflow needs
Choose the Molecular Devices automation system that will elevate your research
Place your order by November 22, 2024
We guarantee delivery by December 31, 2024
And don't worry about installation – remember, we'll be there in Q1 2025 to provide two days of FREE training to make sure you start the new year like a pro.
So, ring in the new year with automation systems that will make your research soar!
Using the power of T-cells with organoids and spheroids for cancer therapy and research
Immunotherapy, which leverages the immune system to specifically target cancer cells, is gaining traction as an additional form of cancer treatment. These therapies include CAR T-cells (Chimeric Antigen Receptor engineered T-cells), tumor-infiltrating lymphocytes (TIL), and other genetically modified T-cells.
Enhancing T-cell recruitment and cytotoxic activity is crucial for successful cancer immunotherapy. In preclinical scientific research, 3D cell models offer advantages over 2D monolayer cultures by better mimicking the immunosuppressive tumor microenvironment (TME). For example, patient-derived organoids (PDOs) are superior to traditional 2D monolayer cultures because they better replicate the physical and chemical cues of the TME.
Are FDA plans enough to boost inclusivity within clinical trials?
In an effort to address diversity in clinical trials, the FDA recently issued draft guidance mandating sponsors to create Diversity Action Plans, aimed at engaging historically underrepresented populations. These plans encourage enrollment goals and strategies tailored to the unique needs of various communities, aiming to ensure therapies reflect the populations that will ultimately use them.
In this article, Molecular Devices' VP of Strategy and Innovation, Shantanu Dhamija, emphasizes that advanced technologies like induced pluripotent stem cells (iPSCs) could help alleviate concerns about drug safety in diverse populations. This approach could drive greater participation by providing data on how different demographics respond to therapies, ultimately improving access and outcomes across healthcare.
Combine the options and modules that address your specific research - including objectives, filters, imaging modes, and environmental conditions - to create the perfect automated solution that supports your applications, increases throughput, and streamlines workflows.
Increase assay robustness by tracking a drug's chronic effect on cardiac function over extended periods of time
In this application note, we demonstrate an in vitro model using iPSC-CMs constantly expressing a genetically encoded calcium indicator for monitoring cell responses to various compounds for an extended period of time (up to 60 days).
Additionally, an optogenetic actuator was used to pace the cardiomyocytes in a noninvasive and reversible manner, mimicking a physiological steady rhythm.
This contactless control and recording of cardiomyocytes cannot be easily achieved through conventional electrical stimulation.
We are excited to announce the launch of SoftMax Pro 7.3.1 Software and SoftMax Pro 7.3.1 GxP Software Suite!
SoftMax® Pro 7.3.1 Standard and GxP Software include several new features, formula updates, and enhancements.
Key features included in the GxP edition:
The system Audit Trail can now be exported to a .csv format.
Document Security enhanced to ensure all changes to SoftMax Pro documents can occur only within the application.
Open dialog window now displays only the folder and documents from the Project user are logged into.
Key features included in the Standard and GxP edition:
Fully validated with Windows 11 Enterprise and Windows 11 Professional 23H2; Windows Server 2022; Microsoft SQL Server 2022
Bulk Export feature features the ability to export multiple documents from different folders with included support via the Automation API.
Tool tips translated into Simplified Chinese.
The Formula Editor Check Syntax function and formula syntax have been improved to prevent an error that occurred due to the number of parentheses in the formula. This error became apparent after a user updated the SoftMax Pro Software from a version prior to 7.3.
EZinCert information can now be copied and pasted from Microsoft Edge and Google Chrome
For a detailed description on each of these new additions to this version, please refer to the Release Notes.
Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.
